Related Experiment Video

Updated: May 29, 2025

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

34.5K

Amyotrophic Lateral Sclerosis (ALS) Type 8: A Narrative Review

Billy McBenedict1, Wilhelmina N Hauwanga2, Uzma Nezam1

  • 1Neurosurgery, Fluminense Federal University, Niterói, BRA.

Cureus
|February 3, 2025
PubMed

Insights

Amyotrophic lateral sclerosis type 8 (ALS8) is a rare genetic ALS subtype caused by VAPB gene mutations. Current treatments offer limited benefits, necessitating research into novel gene therapies and subtype-specific interventions for improved patient care.

Area of Science:

  • Neuroscience
  • Genetics
  • Rare Diseases

Background:

  • Amyotrophic lateral sclerosis type 8 (ALS8) is a rare familial subtype of ALS.
  • It is caused by mutations in the vesicle-associated membrane protein-associated protein B (VAPB) gene, notably the p.P56S mutation.
  • ALS8 presents with distinct features: slower progression, earlier onset, severe cramping, fasciculations, tremors, and cognitive/behavioral issues.

Purpose of the Study:

  • To review current therapeutic strategies for ALS8.
  • To discuss the unique clinical trajectory and challenges in treating this rare ALS subtype.
  • To explore potential pathways for innovative, subtype-specific interventions.

Main Methods:

  • This study is a narrative review.
  • It synthesizes existing literature on ALS8 genetics, clinical features, and therapeutic approaches.
  • Focuses on challenges and future directions for ALS8 treatment.

Main Results:

  • Current pharmacological treatments (riluzole, edaravone, etc.) offer modest benefits and do not target the genetic cause.
  • Emerging therapies like gene therapy and RNA-based interventions show promise but face clinical hurdles.
  • Symptom management (respiratory, nutritional, psychological) is vital for patient quality of life.

Conclusions:

  • ALS8's rarity, variable presentation, and limited data challenge therapeutic development.
  • Multidisciplinary and targeted approaches are essential for optimizing care.
  • Further research into subtype-specific interventions is crucial for advancing ALS8 treatment.
Keywords:
als type 8 (als8)amyotrophic lateral sclerosis (als)fus mutationsgene therapyprecision medicinerna-based therapiesstem cell treatmentssymptom managementunfolded protein response (upr)vapb gene mutation

More Related Videos

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.0K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.5K

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
447
Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
116.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K